Piezo1 agonist 1-d2
Piezo1 agonist 1-d2 is a Piezo1 agonist and osteogenesis promoter with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates Piezo1 and induces calcium ion influx in mesenchymal stem cells. Piezo1 agonist 1-d2 activates the Erk signaling pathway and promotes osteogenesis of mesenchymal stem cells. Piezo1 agonist 1-d2 alleviates disuse osteoporosis in a hindlimb unloading rat model. Piezo1 agonist 1-d2 can be used for research on osteoporosis.
For research use only. We do not sell to patients.
- CAS No.: 3058199-62-2
- Formula: C16H13D2Cl2N5OS2
- Molecular Weight:430.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
EC50: 2.21 μM (Piezo1)
In Vitro
Piezo1 agonist 1-d2 (compound 12a) (0.125-32 μM; 2 h) potently activates Piezo1 and induces Ca2+ influx in C3H10T1/2 mesenchymal stem cells (MSCs), with an EC50 of 2.21 μM[1].
Piezo1 agonist 1-d2 (3-5 μM; 72 h) promotes osteogenesis of bone marrow mesenchymal stem cells (BMSCs) in a dose-dependent manner, and upregulates the expression of Runx2 and Osxm RNA[1].
Piezo1 agonist 1-d2 (5 μM; 5-15 min) activates the Erk signaling pathway in BMSCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:bone marrow mesenchymal stem cells (BMSCs)
-
Concentration:3, 5 μM
-
Incubation Time:72 h
-
Result:Significantly upregulated Runx2 mRNA levels at 3 μM, but did not significantly alter Osx mRNA levels.
Significantly upregulated both Runx2 mRNA levels and Osx mRNA levels at 5 μM.
-
Cell Line:bone marrow mesenchymal stem cells (BMSCs)
-
Concentration:5 μM
-
Incubation Time:5, 10, 15 min
-
Result:Significantly increased p-Erk levels at 5 min.
Showed higher p-Erk/Erk ratios at 5, 10, and 15 min compared to vehicle control.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (2 months old, hindlimb-unloading osteoporosis model)[1]
-
Dosage:5 μM/kg
-
Administration:i.p.; 5 doses on days 1, 4, 7, 10, 13 after hindlimb unloading initiation
-
Result:Increased bone volume fraction (BV/TV), trabecular number (Tb.N.), and reduced trabecular separation (Tb.Sp.) compared to untreated hindlimb-unloading group.
Significantly increased Alp fluorescent area (osteogenic marker) relative to untreated hindlimb-unloading group, with osteogenesis levels nearly matching weight-bearing control rats.
Showed no significant liver or kidney toxic side effects during treatment.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 3058199-62-2
-
Molecular Weight 430.37
-
Formula C16H13D2Cl2N5OS2
-
SMILES
ClC1=C(C(Cl)=CC=C1)C([2H])(SC2=NN=C(S2)C3=CN=C(C=N3)NC[C@@H](C)O)[2H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mesenchymal stromal/stem cell osteogenic differentiation
Mesenchymal stromal/stem cells can be induced toward an osteoblast-like lineage in vitro by culture in osteogenic medium containing dexamethasone, ascorbic acid or ascorbate-2-phosphate, and β-glycerophosphate; the differentiation process is commonly evaluated by alkaline phosphatase activity, osteogenic marker expression, collagenous matrix formation, and calcium-rich matrix mineralization. The main readouts are alkaline phosphatase activity as an early osteogenic marker and Alizarin Red S staining as a calcium-deposit readout for mineralized extracellular matrix; Alizarin Red S can be inspected microscopically or extracted and measured colorimetrically at 405 nm.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)